GlaxoSmithKline is planning to double the production capacity of its flu vaccine manufacturing plant in Dresden, Germany, to respond to the growing global demand for the drugs, according to the U.K. firm. An analysis indicates GSK and other flu vaccine manufacturers, such as Sanofi Aventis, hope to gain market share while a major competitor, Chiron, faces production problems in the buildup to this year's flu season.

Full Story:

Related Summaries